Biocon’s affordable therapy for the treatment of Hepatitis C

Biocon’s affordable therapy for the treatment of Hepatitis C
Hepatitis C, a viral disease is a silent epidemic that causes many deaths annually, especially in the countries with developing economies. In India, Biocon has introduced recently an affordable and novel therapy to treat the people infected with Hepatitis C virus. CIMIVIR-L is a pill introduced by Biocon, which is a fixed-dose combination of Ledipasvir 90 and Sofosbuvir 400, and is found to possess high cure rate ranging from 94-99%. It is once-a-day oral therapy offering effective treatment in patients than the existing therapies.
How to cite this article:
Hameedunissa Begum Shariff. Biocon’s affordable therapy for the treatment of Hepatitis C . BioLim O-Media. 13 April, 2017. 5(4).
Available from: http://archive.biolim.org/omedia/read/BOMA0239.